The dose of chemotherapy and radiation, patient age, and timing of treatment were all associated with the risk of severe hearing loss.
The incidence was highest among Laotian and Chinese Americans.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Reductions in oropharynx cancer incidence should be seen among young and middle-aged adults.
The phase 3 CheckMate 651 trial showed prolonged overall survival and durable responses in specific subsets of patients.
Avelumab plus cetuximab and radiotherapy did not improve progression-free survival over standard care in cisplatin-fit or -unfit patients.
Gemcitabine plus cisplatin reduced the risk of death by 28%.
A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population.
Response endpoints were not strongly correlated with overall survival at the trial level.
The test can accurately detect cancer and predict where it is located, according to researchers.
Survey-based study determined the association between patients’ perception of aesthetic outcome and psychosocial function after undergoing ablation with this complex procedure.
Treatment-related toxicities were less likely with the lobaplatin-based regimen.
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Researchers found associations between epigenetic age acceleration, inflammation, and fatigue in cancer patients.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.
The combination significantly prolonged progression-free survival.